Full Press Release Details
Lexaria Enters Licensing Agreement with Canadian Cannabis
Chocolate Manufacturer
Kelowna, British Columbia January 25, 2018 Lexaria
Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the Company or Lexaria ) a drug
delivery platform innovator, announces it has entered a definitive technology
licensing agreement (the Agreement ) with Cannfections Group Inc. whereby
Lexaria is providing its patented DehydraTECHTM technology to empower
next-generation performance in cannabis infused chocolates and candies to be
developed and sold in Canada and internationally.
Cannfections Group Inc. is an infused chocolate and gummies
contract manufacturer that has been newly established by one of Canada s leading
chocolate companies with over eighty-five years of experience in producing high
quality chocolate and confectionary products that meet the industry s strictest
quality requirements, as a pending entrant into the Licensed Producer program
for cannabis infused products. The founders of Cannfections currently
manufacture chocolate retail products for several leading international and
domestic chocolate brands.
Under the terms of the Agreement, Lexaria can offer other
licensee partners the option of utilizing Cannfection s formulation and
manufacturing expertise to produce cannabis infused, DehydraTECH -powered
chocolates and gummies where approved. This Agreement is expected to lead to new
product entries for Canadian cannabis edibles, and exportation to the increasing
number of other international markets where permitted around the world. The term
of the agreement is seven years.
By licensing our technology to Cannfections, Lexaria can now
offer its commercial clients the expertise of one of Canada s oldest and most
established chocolatiers utilizing next-generation DehydraTECHTM
technology, said Chief Executive Officer Chris Bunka. This is a long term
strategic relationship meant to offer technology, value and expertise to
Licensed Producers wanting to offer the highest quality chocolate edibles
available in Canada once permitted under Health Canada regulations.
Lexaria s patented DehydraTECH technology is focused on
improved delivery methodologies of many commonly used active
pharmaceutical ingredient ( API ) substances. As such, it provides an additional
layer of effectiveness that is designed to harmonize with the intellectual
property of third parties. Both patented and generic API substances can utilize
Lexaria s patented technology. Lexaria s long term strategy is to partner with
the world s leading firms as they deliver best-of-class products to their
existing large consumer groups.
Lexaria is presently investigating and will continue to pursue
additional technologies that could deliver value to its growing portfolio of
patented technologies.
Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECHTM delivery technology. Lexaria s
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp) and on Facebook
FOR FURTHER INFORMATION PLEASE CONTACT:
Alex Blanchard, Communications Manager
NetworkNewsWire (NNW)
About Cannfections Group Inc.
Group Inc. is the first company in Canada to announce entry into the Cannabis
Infused Confectionary market for Adult Use. Cannfections will lead the industry
with responsible, tested, consistent and delicious Cannabis Infused confections.
Cannfections is backed by a team of confection industry experts with over 85
years of experience in producing amazing products that delight our customers!
Cannfections Group Inc is about to launch in Canada. For more information about
our cannabis infused chocolate, gummies and candies contract manufacturing
services please contact us at info@cannfections.ca
FORWARD-LOOKING STATEMENTS
This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing cannabinoids or any
other active ingredient, or that the Cannfections license agreement will
successfully produce benefits to the Company. There is no assurance that any
planned corporate activity, scientific research or study, business venture,
technology licensing pursuit, patent application or allowance, consumer study,
or any initiative will be pursued, or if pursued, will be successful. There is
no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).
Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.